{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-111586","form_type":"8-K","ticker":"MNKD","cik":"0000899460","company_name":"MANNKIND CORP","filed_at":"2025-08-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.644931+00:00","generated_at":"2026-05-17T09:52:33.665800+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"MannKind receives $5M upfront from United Therapeutics for new product option exercise","bullets":["MannKind entered First Amendment with United Therapeutics to exercise option for an additional development product using its Technosphere platform.","MannKind receives $5M upfront payment and is eligible for up to $35M in milestone payments.","MannKind will manufacture clinical trial materials; United Therapeutics will conduct all other preclinical and clinical development.","MannKind will earn 10% royalties on net sales of the additional product if approved.","United Therapeutics exercised withdrawal option retains right to withdraw the exercise for the new agent."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-111586","json":"https://secwatch.observer/filing/0000950170-25-111586.json","markdown":"https://secwatch.observer/filing/0000950170-25-111586.md","text":"https://secwatch.observer/filing/0000950170-25-111586.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000095017025111586/0000950170-25-111586-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000095017025111586/mnkd-20250824.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T09:52:33.665800+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}